A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol-Reference-Cited by-同舟云学术

A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol

Published:2024-09-07 Issue:1 Volume:23 Page:
ISSN:1472-684X
Container-title:BMC Palliative Care
language:en
Short-container-title:BMC Palliat Care

Author:

Palma David A.,Giuliani Meredith E.,Correa Rohann J. M.,Schneiders Famke L.,Harrow Stephen,Guckenberger Matthias,Zhang Tina,Bahig Houda,Senthi Sashendra,Chung Peter,Olson Robert,Lock Michael,Raman Srinivas,Bauman Glenn S.,Lok Benjamin H.,Laba Joanna M.,Glicksman Rachel M.,Nguyen Timothy K.,Lang Pencilla,Helou Joelle,Goodman Christopher D.,Mendez Lucas C.,van Rossum Peter S. N.,Warner Andrew,Gaede Stewart,Allan Alison L.

Funder

London Health Sciences Foundation

Ontario Institute for Cancer Research

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s12904-024-01548-7.pdf

Reference27 articles.

1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol Off J Am Soc Clin Oncol. 1995;13(1):8–10.

2. Palma DA, Olson R, Harrow S, Correa RJM, Schneiders F, Haasbeek CJA, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019;19(1):816.

3. Bauman GS, Corkum MT, Fakir H, Nguyen TK, Palma DA. Ablative radiation therapy to restrain everything safely treatable (ARREST): study protocol for a phase I trial treating polymetastatic cancer with stereotactic radiotherapy. BMC Cancer. 2021;21(1):405.

4. Olson R, Mathews L, Liu M, Schellenberg D, Mou B, Berrang T, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial. BMC Cancer. 2020;20(1):380.

5. Ashworth AB, Senan S, Palma DA, Riquet M, Ahn YC, Ricardi U, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer. 2014;15(5):346–55.